<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22809" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Hepcidin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chambers</surname>
            <given-names>Kevin</given-names>
          </name>
          <aff>Campbell University School of OM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashraf</surname>
            <given-names>Muhammad A.</given-names>
          </name>
          <aff>University of New England School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kevin Chambers declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Ashraf declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22809.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hepcidin is a peptide hormone produced in the liver that plays a crucial role in iron homeostasis. Iron is an essential part of oxygen transport within the body and is present in hemoglobin, myoglobin, and the electron transport chain. Serum iron levels must be tightly regulated to ensure an adequate supply is available for hemoglobin synthesis during erythropoiesis, without allowing iron overload to occur in the body. Hepcidin decreases the level of iron by reducing dietary absorption and inhibiting iron release from cellular storage. Hepcidin production increases when iron levels rise above the normal range of 65 to 175 mcg/dL in males and 50 to 170 mcg/dL in females.</p>
        <p>Hepcidin is an acute-phase reactant, one of many molecules whose plasma concentration changes in response to inflammation. During states of acute or chronic inflammation, levels of hepcidin and other acute-phase reactants increase, leading to a decrease in serum iron levels as hepcidin levels rise. Increased hepcidin correlates with the pathophysiology of anemia of chronic disease; the increase in inflammation causes a reduction in serum iron levels because the increase in hepcidin reduces iron transport out of cells. Conversely, a deficiency in hepcidin production can result in iron overload, as seen in hereditary hemochromatosis.<xref ref-type="bibr" rid="article-22809.r1">[1]</xref><xref ref-type="bibr" rid="article-22809.r2">[2]</xref></p>
      </sec>
      <sec id="article-22809.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>Hepatocytes are primarily responsible for the synthesis of hepcidin. Hepcidin is produced initially as a preprohormone with eighty-four amino acids. It is then cleaved into a prohormone, which gets cleaved again, forming hepcidin. The final hepcidin protein has 25 amino acids. Many factors influence hepcidin gene expression. Up-regulation occurs during inflammatory states and is primarily mediated by IL-6, a pro-inflammatory cytokine released from a variety of cell types. Transferrin, an iron-binding transport molecule in the blood, can also up-regulate hepcidin production, signaling that iron storage in the serum is adequate and that the release of iron from intracellular storage is not currently needed. Erythroferrone is a hormone produced by erythroblasts during erythropoiesis. It down-regulates the hepcidin gene expression. Hepcidin gene is also downregulated during hypoxic conditions. Both erythroferrone and hypoxia signal a demand for iron to construct new hemoglobin molecules.<xref ref-type="bibr" rid="article-22809.r3">[3]</xref><xref ref-type="bibr" rid="article-22809.r4">[4]</xref><xref ref-type="bibr" rid="article-22809.r2">[2]</xref></p>
      </sec>
      <sec id="article-22809.s3" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>Iron plays a central role in the maturation and proper functioning of erythrocytes. It is essential to hematologic function. Hepcidin acts as a critical regulator for serum iron levels by modulating the release of iron from intracellular storage sites. When hepcidin levels become elevated, iron remains in its intracellular storage form, bound to the molecule ferritin. Hepcidin forms a connection between the immune system and the hematologic system. The theory is that during inflammatory states, hepcidin levels increase, so that serum iron levels decrease. The decreased serum iron levels prevent the invading pathogen from using the host&#x02019;s iron stores for its growth. Therefore, hepcidin is an essential mediator for immune defenses as well as hematologic functioning.<xref ref-type="bibr" rid="article-22809.r5">[5]</xref></p>
      </sec>
      <sec id="article-22809.s4" sec-type="Function">
        <title>Function</title>
        <p>Once released into circulation from hepatocytes, hepcidin regulates plasma iron levels through interactions with ferroportin-1. Ferroportin is an iron export transmembrane protein present in the macrophages and the enterocytes. When hepcidin binds to ferroportin, it causes the cell to target the hepcidin-ferroportin complex for lysosomal degradation.&#x000a0; The cell types most affected by this interaction are duodenal enterocytes and reticuloendothelial macrophages. Duodenal enterocytes absorb dietary iron, and reticuloendothelial macrophages store iron recovered from degraded erythrocytes in the bone marrow, liver, and spleen. The degradation of ferroportin blocks iron absorption from enterocytes and iron mobilization from the macrophages.<xref ref-type="bibr" rid="article-22809.r6">[6]</xref><xref ref-type="bibr" rid="article-22809.r7">[7]</xref></p>
      </sec>
      <sec id="article-22809.s5" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>Serum iron studies are useful to evaluate the status of iron homeostasis in the body. This panel of blood tests typically includes serum iron, transferrin, or total iron-binding capacity (TIBC), ferritin, and the percentage of transferrin saturation. A level of urinary excreted hepcidin can also be measured. A complete blood count (CBC) may be used to evaluate signs of anemia.</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum Iron: circulating iron with a normal range of 65 to 175 mcg/dL in males and 50 to 170 mcg/dL in females</p>
          </list-item>
          <list-item>
            <p>Ferritin: predominantly an intracellular iron storage molecule, serum ferritin directly correlates to total body iron stores - the normal range is 20 to 250 mcg/L in males and 10 to 120 mcg/L in females</p>
          </list-item>
          <list-item>
            <p>Transferrin or total iron-binding capacity: a measure of transferrin molecules available to bind iron - TIBC is an indirect measurement</p>
          </list-item>
          <list-item>
            <p>Transferrin saturation: a calculated measurement that reflects the amount of bound serum iron using the equation: serum iron divided by TIBC</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22809.s6" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Hereditary Hemochromatosis</bold>
</p>
        <p>An autosomal recessive defect in the HFE gene, resulting in decreased hepcidin production. HFE mutations are more prevalent in individuals of European descent. Decreased hepcidin results in increased iron uptake from diet and increased iron mobilization from macrophages. Continued iron absorption despite adequate serum levels can lead to iron overload (total body iron exceeds 20g). Symptoms of hemochromatosis are secondary to iron deposition in bodily tissue and typically present in the 4th and 5th decade of life for men and women, respectively. The classic triad includes skin hyperpigmentation, liver cirrhosis, and diabetes mellitus. Additional findings include dilated cardiomyopathy, hypogonadism, arthropathy, and hypothyroidism. Hemochromatosis patients also have increased infection risk now that serum iron levels cannot decrease during inflammatory states. The diagnostic basis is iron panel results showing an increased serum iron level with increased ferritin (&#x0003e; 200 mcg/L) and transferrin saturation levels (&#x0003e; 45%). Treatment involves lifestyle modifications, therapeutic phlebotomy, and medications. Dietary changes include a diet low in iron, restriction of vitamin C supplements and alcohol, and consuming tea because tannates reduce iron absorption by binding to it. About 1 to 2 therapeutic phlebotomy sessions per week initially to bring ferritin and hemoglobin to the target level and then every 2 to 4 months. The iron-chelating agents like deferoxamine to remove iron from the circulation.<xref ref-type="bibr" rid="article-22809.r8">[8]</xref><xref ref-type="bibr" rid="article-22809.r9">[9]</xref></p>
        <p>
<bold>Anemia of Chronic Disease</bold>
</p>
        <p>Anemia of chronic disease is the second most common cause of anemia after iron deficiency anemia. It is associated with a variety of disease states, including infection, neoplasm, chronic kidney disease, and autoimmune conditions like systemic lupus erythematosus. Hepcidin is an acute-phase protein, and upregulation is by interleukin-6 (IL-6) and other proinflammatory cytokines. As a result, hepcidin causes enterocytes and macrophages to degrade ferroportin, reducing absorption and promoting storage, respectively. Serum iron levels decline in an attempt to deprive rapidly dividing cells and invading microbes from nutrients. Anemia of chronic disease typically begins as a mild to moderate normocytic normochromic anemia denoted by a hemoglobin concentration of 8 to 9.5 g/dL. The anemia can progress to microcytic and hypochromic if the inflammatory conditions remain. Presenting symptoms are often nonspecific signs of anemia, including fever, pallor, and fatigue. An iron panel would show a decrease in serum iron level despite an increase in ferritin because of intracellular iron sequestration. Treatment with iron supplementation is often not beneficial as the issue lies with iron availability rather than deficiency. It is crucial to treat the underlying condition to prevent further inflammation.<xref ref-type="bibr" rid="article-22809.r10">[10]</xref></p>
      </sec>
      <sec id="article-22809.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Hepcidin plays a role in innate immunity through its interactions with IL-6 and other pro-inflammatory cytokines. The ability to sequester iron within cells to prevent its availability for pathogenic or neoplastic growth appears to be largely dependent on hepcidin stimulation by IL-6. This innate defense may help protect against many pathogens, including streptococcal and malarial species.<xref ref-type="bibr" rid="article-22809.r11">[11]</xref></p>
        <p>Several hepcidin agonists are currently in development and may become a viable treatment for hereditary hemochromatosis. Currently, phlebotomy is the mainstay of treatment for iron overload states, but a hepcidin agonist could help alleviate the symptoms from the deficient natural hepcidin.<xref ref-type="bibr" rid="article-22809.r12">[12]</xref></p>
        <p>Hepcidin plays a central role in iron transport and utilization and is, therefore, an important marker of iron bioavailability.</p>
      </sec>
      <sec id="article-22809.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22809&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22809">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22809/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22809">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22809.s9">
        <title>References</title>
        <ref id="article-22809.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Impact of chronic and acute inflammation on extra- and intracellular iron homeostasis.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>106</volume>
            <issue>Suppl 6</issue>
            <fpage>1581S</fpage>
            <page-range>1581S-1587S</page-range>
            <pub-id pub-id-type="pmid">29070546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bennoun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devaux</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beaumont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grandchamp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaulont</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2001</year>
            <month>Jul</month>
            <day>17</day>
            <volume>98</volume>
            <issue>15</issue>
            <fpage>8780</fpage>
            <page-range>8780-5</page-range>
            <pub-id pub-id-type="pmid">11447267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wessling-Resnick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knutson</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Hepcidin regulation of iron transport.</article-title>
            <source>J Nutr</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>138</volume>
            <issue>11</issue>
            <fpage>2284</fpage>
            <page-range>2284-8</page-range>
            <pub-id pub-id-type="pmid">18936232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latour</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wlodarczyk</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gineste</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Coppin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kautz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia.</article-title>
            <source>Haematologica</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-68</page-range>
            <pub-id pub-id-type="pmid">27658439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bennoun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Porteu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mativet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beaumont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grandchamp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sirito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sawadogo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaulont</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Severe iron deficiency anemia in transgenic mice expressing liver hepcidin.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2002</year>
            <month>Apr</month>
            <day>02</day>
            <volume>99</volume>
            <issue>7</issue>
            <fpage>4596</fpage>
            <page-range>4596-601</page-range>
            <pub-id pub-id-type="pmid">11930010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemeth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The role of hepcidin in iron metabolism.</article-title>
            <source>Acta Haematol</source>
            <year>2009</year>
            <volume>122</volume>
            <issue>2-3</issue>
            <fpage>78</fpage>
            <page-range>78-86</page-range>
            <pub-id pub-id-type="pmid">19907144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Viatte</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lou</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Bennoun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beaumont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Vaulont</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis.</article-title>
            <source>Nat Genet</source>
            <year>2003</year>
            <month>May</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-101</page-range>
            <pub-id pub-id-type="pmid">12704388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLaren</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Reboussin</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gordeuk</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Acton</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Speechley</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sholinsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dawkins</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Snively</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Eckfeldt</surname>
                <given-names>JH</given-names>
              </name>
              <collab>Hemochromatosis and Iron Overload Screen (HEIRS) Study Research Investigators</collab>
            </person-group>
            <article-title>Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening.</article-title>
            <source>Can J Gastroenterol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>923</fpage>
            <page-range>923-30</page-range>
            <pub-id pub-id-type="pmid">19018338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Means</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Hepcidin and iron regulation in health and disease.</article-title>
            <source>Am J Med Sci</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>345</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">22627267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madu</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ughasoro</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Anaemia of Chronic Disease: An In-Depth Review.</article-title>
            <source>Med Princ Pract</source>
            <year>2017</year>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">27756061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodriguez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gabayan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ganz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nemeth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bulut</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6.</article-title>
            <source>Infect Immun</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>2</issue>
            <fpage>745</fpage>
            <page-range>745-52</page-range>
            <pub-id pub-id-type="pmid">24478088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22809.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanchette</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Manz</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Torti</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Torti</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Modulation of hepcidin to treat iron deregulation: potential clinical applications.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2016</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-86</page-range>
            <pub-id pub-id-type="pmid">26669208</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
